FALSEJun 30, 20232023Q2000162442212-310.100016244222023-01-012023-06-3000016244222022-01-012022-06-30iso4217:EURiso4217:EURxbrli:shares00016244222022-12-3100016244222023-06-3000016244222021-12-3100016244222022-06-300001624422eryp:CellTherapyManufacturingFacilityToCatalentMember2022-04-012022-04-300001624422ifrs-full:IssuedCapitalMember2021-12-310001624422ifrs-full:SharePremiumMember2021-12-310001624422ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2021-12-310001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2021-12-310001624422ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2021-12-310001624422ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2022-01-012022-06-300001624422ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2022-01-012022-06-300001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-01-012022-06-300001624422ifrs-full:SharePremiumMember2022-01-012022-06-300001624422ifrs-full:IssuedCapitalMember2022-06-300001624422ifrs-full:SharePremiumMember2022-06-300001624422ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2022-06-300001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-06-300001624422ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2022-06-300001624422ifrs-full:IssuedCapitalMember2022-12-310001624422ifrs-full:SharePremiumMember2022-12-310001624422ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2022-12-310001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2022-12-310001624422ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2022-12-310001624422ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2023-01-012023-06-300001624422ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2023-01-012023-06-300001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-01-012023-06-300001624422ifrs-full:SharePremiumMember2023-01-012023-06-300001624422ifrs-full:IssuedCapitalMember2023-01-012023-06-300001624422ifrs-full:IssuedCapitalMember2023-06-300001624422ifrs-full:SharePremiumMember2023-06-300001624422ifrs-full:RetainedEarningsExcludingProfitLossForReportingPeriodMember2023-06-300001624422ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember2023-06-300001624422ifrs-full:RetainedEarningsProfitLossForReportingPeriodMember2023-06-3000016244222013-05-012013-05-3100016244222017-11-012017-11-30iso4217:USD00016244222023-04-13xbrli:pure0001624422eryp:AkkadianPartnersFundMember2023-04-130001624422eryp:ErytechAndPherecydesMergerMember2023-05-15xbrli:shares00016244222022-04-012022-04-30eryp:employee00016244222022-05-25eryp:trancheryp:subsidiary0001624422eryp:ERYTECHPharmaIncMember2023-01-012023-06-30eryp:uSD_per_EUR00016244222022-01-012022-12-310001624422country:FR2022-01-012022-06-300001624422country:FR2023-01-012023-06-300001624422country:US2022-01-012022-06-300001624422country:US2023-01-012023-06-300001624422eryp:ReverseStockSplitMember2023-07-260001624422eryp:ReverseStockSplitMember2023-07-270001624422eryp:ReverseStockSplitMember2023-09-180001624422eryp:ReverseStockSplitMember2023-07-272023-07-270001624422eryp:ResearchTaxCreditMember2022-01-012022-06-300001624422eryp:ResearchTaxCreditMember2023-01-012023-06-300001624422eryp:SubsidiesMember2022-01-012022-06-300001624422eryp:SubsidiesMember2023-01-012023-06-300001624422eryp:OtherIncomesMember2022-01-012022-06-300001624422eryp:OtherIncomesMember2023-01-012023-06-300001624422eryp:DisposalOfTangibleAssetsMember2022-01-012022-06-300001624422eryp:DisposalOfTangibleAssetsMember2023-01-012023-06-300001624422eryp:CellTherapyManufacturingFacilityToCatalentMember2022-04-222022-04-220001624422eryp:CellTherapyManufacturingFacilityToCatalentMember2022-04-220001624422eryp:ResearchAndDevelopmentMembereryp:ResearchAndDevelopmentExpensesMember2022-01-012022-06-300001624422eryp:ResearchAndDevelopmentExpensesMembereryp:RegulatoryMember2022-01-012022-06-300001624422eryp:ResearchAndDevelopmentExpensesMembereryp:ClinicalStudiesMember2022-01-012022-06-300001624422eryp:ResearchAndDevelopmentExpensesMember2022-01-012022-06-300001624422eryp:ResearchAndDevelopmentMembereryp:ResearchAndDevelopmentExpensesMember2023-01-012023-06-300001624422eryp:ResearchAndDevelopmentExpensesMembereryp:RegulatoryMember2023-01-012023-06-300001624422eryp:ResearchAndDevelopmentExpensesMembereryp:ClinicalStudiesMember2023-01-012023-06-300001624422eryp:ResearchAndDevelopmentExpensesMember2023-01-012023-06-300001624422eryp:GeneralAndAdministrativeExpensesMember2022-01-012022-06-300001624422eryp:GeneralAndAdministrativeExpensesMember2023-01-012023-06-300001624422eryp:BSPCE20191Member2023-01-012023-06-300001624422eryp:BSPCE20192Member2023-01-012023-06-300001624422eryp:BSPCE20194Member2023-01-012023-06-300001624422eryp:BSPCE20212Member2023-01-012023-06-300001624422eryp:BSPCE20213Member2023-01-012023-06-300001624422eryp:BSPCE20214Member2023-01-012023-06-300001624422eryp:BSPCE20191Member2023-06-300001624422eryp:BSPCE20192Member2023-06-300001624422eryp:BSPCE20194Member2023-06-300001624422eryp:BSPCE20212Member2023-06-300001624422eryp:BSPCE20213Membereryp:TrancheThreeMember2023-06-300001624422eryp:TrancheFourMembereryp:BSPCE20213Member2023-06-300001624422eryp:BSPCE20214Member2023-06-300001624422srt:MinimumMembereryp:BSPCE20191Member2023-01-012023-06-300001624422srt:MaximumMembereryp:BSPCE20191Member2023-01-012023-06-300001624422eryp:BSPCE20192Membersrt:MinimumMember2023-01-012023-06-300001624422srt:MaximumMembereryp:BSPCE20192Member2023-01-012023-06-300001624422eryp:BSPCE20194Membersrt:MinimumMember2023-01-012023-06-300001624422eryp:BSPCE20194Membersrt:MaximumMember2023-01-012023-06-300001624422eryp:BSPCE20212Membersrt:MinimumMember2023-01-012023-06-300001624422eryp:BSPCE20212Membersrt:MaximumMember2023-01-012023-06-300001624422eryp:BSPCE20213Membersrt:MinimumMember2023-01-012023-06-300001624422srt:MaximumMembereryp:BSPCE20213Member2023-01-012023-06-300001624422eryp:BSPCE20214Membersrt:MinimumMember2023-01-012023-06-300001624422srt:MaximumMembereryp:BSPCE20214Member2023-01-012023-06-300001624422eryp:AGA2022Member2023-01-012023-06-300001624422eryp:AGA2022Member2023-06-300001624422srt:MinimumMember2023-01-012023-06-30utr:Y0001624422srt:MaximumMember2023-01-012023-06-300001624422eryp:AGAMember2022-01-012022-06-300001624422eryp:AGAMembereryp:EmployeesMember2022-01-012022-06-300001624422eryp:ExecutiveOfficersAndExecutiveCommitteeMembereryp:AGAMember2022-01-012022-06-300001624422eryp:SOMember2022-01-012022-06-300001624422eryp:SOMembereryp:EmployeesMember2022-01-012022-06-300001624422eryp:SOMembereryp:ExecutiveOfficersAndExecutiveCommitteeMember2022-01-012022-06-300001624422eryp:EmployeesMember2022-01-012022-06-300001624422eryp:ExecutiveOfficersAndExecutiveCommitteeMember2022-01-012022-06-300001624422eryp:AGAMember2023-01-012023-06-300001624422eryp:ExecutiveOfficersAndExecutiveCommitteeMembereryp:AGAMember2023-01-012023-06-300001624422eryp:BSAMember2023-01-012023-06-300001624422eryp:EmployeesMembereryp:BSAMember2023-01-012023-06-300001624422eryp:ExecutiveOfficersAndExecutiveCommitteeMembereryp:BSAMember2023-01-012023-06-300001624422eryp:BoardMembersMembereryp:BSAMember2023-01-012023-06-300001624422eryp:SOMember2023-01-012023-06-300001624422eryp:SOMembereryp:EmployeesMember2023-01-012023-06-300001624422eryp:SOMembereryp:ExecutiveOfficersAndExecutiveCommitteeMember2023-01-012023-06-300001624422eryp:EmployeesMember2023-01-012023-06-300001624422eryp:ExecutiveOfficersAndExecutiveCommitteeMember2023-01-012023-06-300001624422eryp:BoardMembersMember2023-01-012023-06-3000016244222022-06-012022-06-3000016244222022-12-312022-12-310001624422ifrs-full:GrossCarryingAmountMemberifrs-full:OtherIntangibleAssetsMember2022-12-310001624422ifrs-full:GrossCarryingAmountMemberifrs-full:OtherIntangibleAssetsMember2023-01-012023-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:OtherIntangibleAssetsMember2023-06-300001624422ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherIntangibleAssetsMember2022-12-310001624422ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherIntangibleAssetsMember2023-01-012023-06-300001624422ifrs-full:AccumulatedDepreciationAndAmortisationMemberifrs-full:OtherIntangibleAssetsMember2023-06-300001624422ifrs-full:OtherIntangibleAssetsMember2022-12-310001624422ifrs-full:OtherIntangibleAssetsMember2023-06-300001624422eryp:PherecydesMember2023-01-012023-06-300001624422eryp:PherecydesMembereryp:IPOsteoarticularInfectionOnProsthesesMember2023-01-012023-06-300001624422eryp:PherecydesMembereryp:IPEndocarditisMember2023-01-012023-06-300001624422eryp:PherecydesMember2023-06-230001624422eryp:PherecydesMember2023-06-300001624422eryp:PherecydesMember2023-05-15eryp:installment00016244222023-06-232023-06-230001624422ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2022-12-310001624422ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2022-12-310001624422ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2022-12-310001624422ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2022-12-310001624422ifrs-full:GrossCarryingAmountMember2022-12-310001624422ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2023-01-012023-06-300001624422ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2023-01-012023-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2023-01-012023-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2023-01-012023-06-300001624422ifrs-full:GrossCarryingAmountMember2023-01-012023-06-300001624422ifrs-full:FixturesAndFittingsMemberifrs-full:GrossCarryingAmountMember2023-06-300001624422ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2023-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:OfficeEquipmentMember2023-06-300001624422ifrs-full:GrossCarryingAmountMemberifrs-full:ConstructionInProgressMember2023-06-300001624422ifrs-full:GrossCarryingAmountMember2023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2022-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2022-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember2022-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2022-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2023-01-012023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2023-01-012023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember2023-01-012023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-01-012023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:FixturesAndFittingsMember2023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember2023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMember2023-06-300001624422ifrs-full:FixturesAndFittingsMember2022-12-310001624422ifrs-full:MachineryMember2022-12-310001624422ifrs-full:OfficeEquipmentMember2022-12-310001624422ifrs-full:ConstructionInProgressMember2022-12-310001624422ifrs-full:FixturesAndFittingsMember2023-06-300001624422ifrs-full:MachineryMember2023-06-300001624422ifrs-full:OfficeEquipmentMember2023-06-300001624422ifrs-full:ConstructionInProgressMember2023-06-300001624422ifrs-full:BuildingsMemberifrs-full:GrossCarryingAmountMember2022-12-310001624422ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2022-12-310001624422ifrs-full:VehiclesMemberifrs-full:GrossCarryingAmountMember2022-12-310001624422ifrs-full:OfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2022-12-310001624422ifrs-full:BuildingsMemberifrs-full:GrossCarryingAmountMember2023-01-012023-06-300001624422ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2023-01-012023-06-300001624422ifrs-full:VehiclesMemberifrs-full:GrossCarryingAmountMember2023-01-012023-06-300001624422ifrs-full:OfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2023-01-012023-06-300001624422ifrs-full:BuildingsMemberifrs-full:GrossCarryingAmountMember2023-06-300001624422ifrs-full:MachineryMemberifrs-full:GrossCarryingAmountMember2023-06-300001624422ifrs-full:VehiclesMemberifrs-full:GrossCarryingAmountMember2023-06-300001624422ifrs-full:OfficeEquipmentMemberifrs-full:GrossCarryingAmountMember2023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2022-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2022-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:VehiclesMember2022-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember2022-12-310001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2023-01-012023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2023-01-012023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:VehiclesMember2023-01-012023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember2023-01-012023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:BuildingsMember2023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:MachineryMember2023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:VehiclesMember2023-06-300001624422ifrs-full:AccumulatedDepreciationAmortisationAndImpairmentMemberifrs-full:OfficeEquipmentMember2023-06-300001624422ifrs-full:BuildingsMember2022-12-310001624422ifrs-full:MachineryMember2022-12-310001624422ifrs-full:VehiclesMember2022-12-310001624422ifrs-full:OfficeEquipmentMember2022-12-310001624422ifrs-full:BuildingsMember2023-06-300001624422ifrs-full:MachineryMember2023-06-300001624422ifrs-full:VehiclesMember2023-06-300001624422ifrs-full:OfficeEquipmentMember2023-06-300001624422eryp:BioserraBuildingMember2023-06-300001624422eryp:PherecydesMembereryp:NantesPremisesMember2023-06-230001624422eryp:PherecydesMembereryp:RousselPremisesMember2023-06-230001624422eryp:PherecydesMembereryp:ResearchEquipmentMember2023-06-230001624422eryp:ResearchTaxCreditPriorYearCarryforwardMember2022-06-300001624422eryp:CIREstimateMember2023-06-300001624422eryp:CIREstimateMembereryp:PherecydesMember2022-06-300001624422eryp:TermDepositsMember2022-12-310001624422eryp:TermDepositsMember2023-06-300001624422eryp:ConvertibleToCashMember2023-06-3000016244222023-05-012023-05-3100016244222023-06-012023-06-300001624422eryp:ConvertibleNotesMember2022-12-310001624422eryp:ConditionalAdvancesMember2022-12-310001624422eryp:BankLoansMember2022-12-310001624422eryp:OtherLiabilitiesMember2022-12-310001624422eryp:ConvertibleNotesMember2023-01-012023-06-300001624422eryp:ConditionalAdvancesMember2023-01-012023-06-300001624422eryp:BankLoansMember2023-01-012023-06-300001624422eryp:OtherLiabilitiesMember2023-01-012023-06-300001624422eryp:ConvertibleNotesMember2023-06-300001624422eryp:ConditionalAdvancesMember2023-06-300001624422eryp:BankLoansMember2023-06-300001624422eryp:OtherLiabilitiesMember2023-06-300001624422ifrs-full:NotLaterThanOneYearMember2023-06-300001624422ifrs-full:LaterThanOneYearAndNotLaterThanThreeYearsMember2023-06-300001624422ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember2023-06-300001624422ifrs-full:LaterThanFiveYearsMember2023-06-3000016244222020-06-242020-06-240001624422eryp:PhagogramMember2023-06-300001624422eryp:EColiMember2023-06-300001624422eryp:PhagosclinMember2023-06-300001624422eryp:PherecydesMember2023-01-012023-06-300001624422eryp:PherecydesMember2023-06-300001624422eryp:FinancialAssetsAtCarryingValueMember2022-12-310001624422ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2022-12-310001624422ifrs-full:FinancialAssetsAtFairValueMember2022-12-310001624422ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2022-12-310001624422eryp:FinancialLiabilitiesAtCarryingValueMember2022-12-310001624422ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2022-12-310001624422ifrs-full:FinancialLiabilitiesAtFairValueMember2022-12-310001624422ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember2022-12-310001624422eryp:FinancialAssetsAtCarryingValueMember2023-06-300001624422ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember2023-06-300001624422ifrs-full:FinancialAssetsAtFairValueMember2023-06-300001624422ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember2023-06-300001624422eryp:FinancialAssetsAtCarryingValueMember2023-06-300001624422ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember2023-06-300001624422ifrs-full:FinancialLiabilitiesAtFairValueMember2023-06-300001624422eryp:ExecutiveOfficersVPAndQualifiedPersonMember2022-01-012022-06-300001624422eryp:ExecutiveOfficersVPAndQualifiedPersonMember2023-01-012023-06-300001624422eryp:ExecutiveCommitteeMember2022-01-012022-06-300001624422eryp:ExecutiveCommitteeMember2023-01-012023-06-300001624422eryp:BoardOfDirectorsMember2022-01-012022-06-300001624422eryp:BoardOfDirectorsMember2023-01-012023-06-300001624422srt:ChiefExecutiveOfficerMember2023-06-23eryp:manager0001624422eryp:ChiefExecutiveOfficerAndDeputyGeneralManagersMember2023-01-012023-06-300001624422srt:MaximumMembereryp:ChiefExecutiveOfficerAndDeputyGeneralManagersMember2023-01-012023-06-300001624422eryp:SQZBiotechnologiesMember2019-01-012019-12-310001624422eryp:SQZBiotechnologiesMemberifrs-full:TopOfRangeMember2019-06-2400016244222019-07-012021-06-30eryp:lease

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________

FORM 6-K

________________________

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of ~~September~~October 2023

Commission File Number: 001-38281

________________________

PHAXIAM Therapeutics S.A.

(Translation of registrant’s name into English)

________________________

60 Avenue Rockefeller

69008 Lyon France

(Address of principal executive office)

________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F S Form 40-F £

~~INCORPORATION~~INFORMATION BYCONTAINED ~~REFERENCE~~IN THIS REPORT ON FORM 6-K

~~This~~Press ~~Report~~Release ondated ~~Form~~October ~~6-K and Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form F-~~3 ~~(File Nos. 333-248953 and 333-259690) and registration statements on Form S-8 (File Nos. 333-222673~~, 333-232670, 333-239429, 333-255900 and 333-265927) of PHAXIAM Therapeutics S.A. (“PHAXIAM” or the “Company”) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished. 2023

~~Half~~On October 3, 2023, Phaxiam Therapeutics S.A. and Vetophage, a company specialized in phage therapy applied to animal health, issued a press release announcing the signature of a long-~~Year~~term ~~Financial~~strategic ~~Report~~research ~~for~~partnership to combine their expertise in the ~~Six~~research ~~Months~~of ~~Ended~~new ~~June~~phages ~~30,~~and ~~2023~~phage-derived proteins (endolysins) in the fight against antimicrobial resistance.

OnPress ~~September~~Release ~~26,~~dated ~~2023,~~October ~~the Company issued a report announcing its financial results for the first half of 2023. The Company’s half-year financial report~~4, ~~including its condensed consolidated financial statements as of June 30,~~ 2023~~, is attached to this Report on Form 6-K as Exhibit 99.1.~~

~~Press~~On ~~Release~~October 4, 2023, Phaxiam Therapeutics S.A. issued a press release announcing that it received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) dated ~~September~~October 213, 2023, informing it that Nasdaq has confirmed that the Company has regained compliance with the minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2).

~~On September 21, 2023, the Company issued a press release to provide a business and financial update for the first half of 2023.~~ The full text of the press ~~release~~releases isare attached as Exhibit 99.1 and Exhibit 99.2 to this Report on Form 6-K and incorporated herein by reference.

~~EXHIBIT INDEX~~ EXHIBITS

Exhibit						Description
99.1						~~Half-Year~~Press ~~Financial~~Release ~~Report,~~dated ~~including~~October ~~the Company’s condensed consolidated financial statements as of June 30~~3, 2023.
99.2						Press Release dated ~~September~~October 214, 2023.
101.INS						XBRL Instance Document
101.SCH						XBRL Taxonomy Extension Schema Document
101.CAL						XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF						XBRL Taxonomy Extension Definition Linkbase Document
101.LAB						XBRL Taxonomy Extension Label Linkbase Document
101.PRE						XBRL Taxonomy Extension Presentation Linkbase Document

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PHAXIAM Therapeutics S.A.

Date:

~~September~~October 265, 2023

By:

/s/ Eric Soyer

Name: Eric Soyer

Name Eric Soyer

Title: Deputy Chief Executive Officer, Chief Financial Officer and Chief Operating Officer

Filing Compare · PHAXIAM Therapeutics S.A.